CVRX Quote, Financials, Valuation and Earnings

Nutriband has a net margin of -97.95% compared to CVRx's net margin of -211%. CVRx's return on equity of -84.64% beat Nutriband's return on equity of -69.58%.

CVRx has a consensus price target of --, signalling upside risk potential of 50.01%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 344.44%. Given that Nutriband has higher upside potential than CVRx, analysts believe Nutriband is more attractive than CVRx.

CVRx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.

CVRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVRx pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

CVRx quarterly revenues are $13.4M, which are larger than Nutriband quarterly revenues of $645.8K. CVRx's net income of -$13.1M is lower than Nutriband's net income of -$1.4M. Notably, CVRx's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVRx is 5.54x versus 19.85x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -97.95% compared to CVRx's net margin of --. CVRx's return on equity of -84.64% beat enVVeno Medical's return on equity of --.

CVRx has a consensus price target of --, signalling upside risk potential of 50.01%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 619.71%. Given that enVVeno Medical has higher upside potential than CVRx, analysts believe enVVeno Medical is more attractive than CVRx.

CVRx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.904%.

CVRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVRx pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

CVRx quarterly revenues are $13.4M, which are larger than enVVeno Medical quarterly revenues of --. CVRx's net income of -$13.1M is lower than enVVeno Medical's net income of -$5.6M. Notably, CVRx's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVRx is 5.54x versus 213.30x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -97.95% compared to CVRx's net margin of -1700%. CVRx's return on equity of -84.64% beat SINTX Technologies's return on equity of -132.95%.

CVRx has a consensus price target of --, signalling upside risk potential of 50.01%. On the other hand SINTX Technologies has an analysts' consensus of -- which suggests that it could grow by 1888.64%. Given that SINTX Technologies has higher upside potential than CVRx, analysts believe SINTX Technologies is more attractive than CVRx.

CVRx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.497, suggesting its more volatile than the S&P 500 by 49.673%.

CVRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVRx pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

CVRx quarterly revenues are $13.4M, which are larger than SINTX Technologies quarterly revenues of $367K. CVRx's net income of -$13.1M is lower than SINTX Technologies's net income of -$6.2M. Notably, CVRx's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVRx is 5.54x versus 0.96x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Beyond Air has a net margin of -97.95% compared to CVRx's net margin of -1673.94%. CVRx's return on equity of -84.64% beat Beyond Air's return on equity of -219.34%.

CVRx has a consensus price target of --, signalling upside risk potential of 50.01%. On the other hand Beyond Air has an analysts' consensus of -- which suggests that it could grow by 510.5%. Given that Beyond Air has higher upside potential than CVRx, analysts believe Beyond Air is more attractive than CVRx.

CVRx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Beyond Air has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.529%.

CVRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVRx pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.

CVRx quarterly revenues are $13.4M, which are larger than Beyond Air quarterly revenues of $798K. CVRx's net income of -$13.1M is higher than Beyond Air's net income of -$13.4M. Notably, CVRx's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVRx is 5.54x versus 7.10x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.